MOgene has launched a new, comprehensive saliva-based Covid-19 test that rapidly inactivates the virus within the collection tube.
Saliva-based collection devices are easier and less painful to use as compared to the existing collection methods, the company said.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As MOgene’s saliva collection kit can inactivate the virus, it will be safer for collection by a non-healthcare specialist.
MOgene CEO Craig Morley said: “The coronavirus pandemic has had a devastating impact on Missouri and the local Bi-State businesses, their employees, and the general population.
“As we are all bracing ourselves for another wave of the virus, it is more important than ever for employers to have access to more simple, painless and accurate Covid-19 testing programmes that will enable them to proactively provide an objective assessment of SARS Co-V-2 infection of their employees.”
Covid-19 testing kits from MOgene’s purpose-built CLIA certified lab in St. Louis, MO will be sent to employers who take part in a testing programme offered by the company.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe programme also comprises onsite training, employee communications support and onsite sample collection.
MOgene Lab director Kazima Saira said: “Our goal is to make it easier for employers to administer the test and get results quickly.
“We expect test results will be returned within 48 hours-72 hours upon receipt of sample.”
The test will be available in the US to nursing homes, assisted living facilities, physician offices and pharma firms intending to screen patients for Covid-19 before they participate in clinical trials.
MOgene noted that it adhered to using saliva as the biological material to test for Covid-19 as it is simple and easy to analyse compared to nasopharyngeal, nasal swabs or blood-based detection technologies.
The company is also developing a general infectious disease respiratory test, anticipated to be available early next year.
